Table 2 Median PBMC cell frequencies at baseline in RA patients subsequently classed as either good or poor responders to anti-TNF therapy

 CD3⁺CD4⁺

53.5^a (44.8–61.6)

52.6 (43.7–61.1)

0.968

 ^aTh1

8.36 (4.87–13.00)

9.34 (5.83–13.70)

0.667

 T_reg

4.49 (3.70–5.44)

4.43 (3.42–5.22)

0.647

 Th17

1.32 (0.73–1.94)

1.37 (0.54–2.09)

0.904

 ex-Th17

0.64 (0.32–1.16)

0.48 (0.22–1.26)

0.451

 ^aIFNγ⁺

8.73 (6.06–12.20)

11.0 (7.14–14.90)

0.131

 IL-17A⁺IFNγ⁺

0.83 (0.19–1.60)

0.24 (0.00–1.16)

0.023*

 IL-17A⁻IFNγ⁺

7.08 (5.15–10.41)

9.18 (6.23–14.28)

0.115

 IL-17A⁺

2.39 (0.95–3.93)

1.82 (0.94–4.51)

0.771

 Th1:Th17

6.0 (4.4–12.8)

7.3 (3.7–18.9)

0.69

 Th1:ex-Th17

12.1 (7.3–24.5)

16.9 (9.1–32.1)

0.422

 Th17:ex-Th17

1.8 (1.4–4.7)

1.9 (1.1–5.2)

0.854

 T_reg:Th17

3.7 (2.5–5.3)

4.1 (2.1–6.0)

0.897